Article
Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis.
BMC cardiovascular disorders - 17 Mar 2022
Xie Qiufen, Xiang Qian, Liu Zhiyan, Mu Guangyan, Zhou Shuang, Zhang Zhuo, Ma Lingyue, Gong Yanjun, Jiang Jie, Cui Yimin
Abstract excerpt
BACKGROUND: Studies show inconsistent results regarding the impact of CYP2C19 genotype on the pharmacodynamics (PD) and clinical outcomes of ticagrelor. With the implementation of genotype-guided individualized antiplatelet therapy, the association between CYP2C19 polymorphism and the efficacy and safety of ticagrelor for patients is still worthy of exploring and studying. METHODS: This systematic review protocol...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.